BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Disitamab Vedotin: trial readouts and FDA decisions

3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 2 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: RemeGen Co., Ltd., Seagen, a wholly owned subsidiary of Pfizer. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2/P3RemeGen Co., Ltd.NCT06221748 DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapGastric Cancer; Gastroesophageal Junction Adenocarcinomarecruiting90
2026-12-11 est.P2Seagen, a wholly owned subsidiary of PfizerNCT04879329 A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2Urothelial Carcinomarecruiting372
2027-01-29 est.P3Seagen, a wholly owned subsidiary of PfizerNCT05911295 Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Urothelial Carcinomaactive not recruiting412

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-01 est.P2RemeGen Co., Ltd.NCT06642545 Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast CancerBreast Cancerrecruiting40
2026-06 est.P2RemeGen Co., Ltd.NCT06178159 DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast CancerBreast Cancerrecruiting40

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.